

Eric Delabesse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2839462/publications.pdf>

Version: 2024-02-01

155
papers

16,880
citations

50276

46
h-index

14759

127
g-index

157
all docs

157
docs citations

157
times ranked

18038
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | <i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. <i>Science</i> , 2003, 302, 415-419. | 12.6 | 3,264 |
| 2 | Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003, 17, 2257-2317. | 7.2 | 2,788 |
| 3 | Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. <i>Journal of Clinical Investigation</i> , 2008, 118, 3132-3142. | 8.2 | 1,531 |
| 4 | Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using <i>real-time</i> quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) a Europe against cancer program. <i>Leukemia</i> , 2003, 17, 2474-2486. | 7.2 | 806 |
| 5 | Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. <i>Lancet</i> , The, 2000, 356, 203-208. | 13.7 | 698 |
| 6 | Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome ⁻ Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 911-918. | 1.6 | 506 |
| 7 | Abnormal intestinal intraepithelial lymphocytes in refractory sprue. <i>Gastroenterology</i> , 1998, 114, 471-481. | 1.3 | 368 |
| 8 | Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R ^β -deficient mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 384-395. | 8.2 | 336 |
| 9 | Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2213-2223. | 1.4 | 313 |
| 10 | Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome ⁺ acute lymphoblastic leukemia: results of the GRAAPH-2003 study. <i>Blood</i> , 2007, 109, 1408-1413. | 1.4 | 300 |
| 11 | Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749. | 1.4 | 281 |
| 12 | TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009, 114, 3285-3291. | 1.4 | 264 |
| 13 | A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). <i>Nature Genetics</i> , 2011, 43, 673-678. | 21.4 | 244 |
| 14 | Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 2225-2232. | 8.2 | 221 |
| 15 | The MLL recombinome of acute leukemias. <i>Leukemia</i> , 2006, 20, 777-784. | 7.2 | 196 |
| 16 | Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. <i>EMBO Journal</i> , 2002, 21, 3039-3050. | 7.8 | 194 |
| 17 | High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. <i>Blood</i> , 2013, 121, 822-829. | 1.4 | 189 |
| 18 | The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 13-21. | 1.4 | 168 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. <i>Haematologica</i> , 2011, 96, 1792-1798. | 3.5 | 164 |
| 20 | Analysis of TCR, pTÎ±, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. <i>Blood</i> , 2003, 101, 2693-2703. | 1.4 | 152 |
| 21 | CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRÂ line. <i>Blood</i> , 2003, 102, 1000-1006. | 1.4 | 148 |
| 22 | Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. <i>Leukemia</i> , 2002, 16, 587-593. | 7.2 | 144 |
| 23 | Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018, 103, 1278-1287. | 3.5 | 129 |
| 24 | Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. <i>Cancer Cell</i> , 2006, 10, 363-374. | 16.8 | 119 |
| 25 | Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 2202-2204. | 1.4 | 114 |
| 26 | CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. <i>Leukemia</i> , 2005, 19, 1948-1957. | 7.2 | 110 |
| 27 | Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. <i>Blood</i> , 2016, 127, 882-892. | 1.4 | 108 |
| 28 | Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. <i>Leukemia</i> , 2006, 20, 1526-1532. | 7.2 | 106 |
| 29 | Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2618-2626. | 1.4 | 100 |
| 30 | Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2514-2523. | 1.6 | 99 |
| 31 | Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. <i>Blood</i> , 2004, 104, 4173-4180. | 1.4 | 94 |
| 32 | FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. <i>Blood</i> , 2003, 102, 2198-2204. | 1.4 | 90 |
| 33 | Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. <i>Blood</i> , 2002, 99, 4547-4553. | 1.4 | 74 |
| 34 | CHK1 as a therapeutic target to bypass chemoresistance in AML. <i>Science Signaling</i> , 2016, 9, ra90. | 3.6 | 73 |
| 35 | TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia. <i>PLoS ONE</i> , 2012, 7, e31605. | 2.5 | 70 |
| 36 | Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015, 6, 8388-8396. | 1.8 | 69 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 483-497. | 8.5 | 68 |
| 38 | Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 1832-1844. | 1.4 | 66 |
| 39 | The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. <i>Blood</i> , 2000, 96, 2254-2261. | 1.4 | 63 |
| 40 | Improved outcome for AML patients over the years 2000â€“2014. <i>Blood Cancer Journal</i> , 2017, 7, 635. | 6.2 | 63 |
| 41 | Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network. <i>American Journal of Hematology</i> , 2014, 89, E244-52. | 4.1 | 59 |
| 42 | Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 131-142. | 2.2 | 57 |
| 43 | Transcriptional Regulation of the SCL Locus: Identification of an Enhancer That Targets the Primitive Erythroid Lineage In Vivo. <i>Molecular and Cellular Biology</i> , 2005, 25, 5215-5225. | 2.3 | 55 |
| 44 | Antileukemic Activity of 2-Deoxy- <i>d</i> -Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with <i>FLT3-ITD</i> or <i>c-KIT</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2364-2373. | 4.1 | 52 |
| 45 | STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752. | 3.5 | 50 |
| 46 | Dexamethasone in hyperleukocytic acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 988-998. | 3.5 | 49 |
| 47 | Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epsteinâ€“Barr virus infection. A different subtype of AILD-TL?. <i>Leukemia</i> , 2002, 16, 2134-2141. | 7.2 | 48 |
| 48 | PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284. | 1.4 | 48 |
| 49 | Prognostic impact of <i>DDX41</i> germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. <i>Blood</i> , 2022, 140, 756-768. | 1.4 | 48 |
| 50 | DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. <i>Leukemia</i> , 2005, 19, 1338-1344. | 7.2 | 47 |
| 51 | Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2013, 98, 1414-1420. | 3.5 | 46 |
| 52 | Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. <i>Blood</i> , 2011, 117, 5719-5722. | 1.4 | 44 |
| 53 | Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. <i>Haematologica</i> , 2015, 100, 780-785. | 3.5 | 42 |
| 54 | The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013, 98, 1711-1717. | 3.5 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2017, 1, 1760-1772. | 5.2 | 41 |
| 56 | Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4 \hat{A} MLL fusion allele. <i>Leukemia</i> , 2007, 21, 1232-1238. | 7.2 | 40 |
| 57 | Characterization of the imprinted polycomb gene <i>L3MBTL</i> , a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. <i>British Journal of Haematology</i> , 2004, 127, 509-518. | 2.5 | 36 |
| 58 | PICALM \hat{A} MLLT10 acute myeloid leukemia: A French cohort of 18 patients. <i>Leukemia Research</i> , 2012, 36, 1365-1369. | 0.8 | 36 |
| 59 | Simultaneous SIL-TAL1 RT-PCR detection of all tald deletions and identification of novel tald variants. <i>British Journal of Haematology</i> , 1997, 99, 901-907. | 2.5 | 34 |
| 60 | Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). <i>Blood</i> , 2006, 108, 3484-3493. | 1.4 | 34 |
| 61 | TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. <i>Haematologica</i> , 2011, 96, 1059-1063. | 3.5 | 34 |
| 62 | Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. <i>Leukemia Research</i> , 2017, 61, 62-67. | 0.8 | 33 |
| 63 | Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. <i>Haematologica</i> , 2017, 102, 1718-1726. | 3.5 | 32 |
| 64 | Major prognostic value of complex karyotype in addition to <i>TP53</i> and <i>IGHV</i> mutational status in first-line chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017, 35, 664-670. | 1.7 | 32 |
| 65 | Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210. | 1.6 | 32 |
| 66 | Germline <i>PAX5</i> mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1424-1428. | 1.4 | 32 |
| 67 | Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV8) episomes in primary effusion lymphoma cells. <i>International Journal of Cancer</i> , 2005, 115, 511-518. | 5.1 | 31 |
| 68 | HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. <i>Leukemia</i> , 2006, 20, 1184-1187. | 7.2 | 31 |
| 69 | Virological and Molecular Characterisation of a New B Lymphoid Cell Line, Established from an AIDS Patient with Primary Effusion Lymphoma, Harboring Both KSHV/HHV8 and EBV Viruses. <i>Leukemia and Lymphoma</i> , 2000, 38, 401-409. | 1.3 | 30 |
| 70 | Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 73769-73780. | 1.8 | 30 |
| 71 | Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. <i>Oncotarget</i> , 2011, 2, 850-861. | 1.8 | 29 |
| 72 | B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. <i>Frontiers in Oncology</i> , 2019, 9, 1374. | 2.8 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714. | 1.4 | 28 |
| 74 | Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3307-3318. | 7.0 | 28 |
| 75 | Primary cutaneous Epstein-Barr virus-related lymphoproliferative disorders in 4 immunosuppressed children. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 74-80. | 1.2 | 27 |
| 76 | Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e185-e187. | 3.5 | 27 |
| 77 | Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients. <i>PLoS ONE</i> , 2010, 5, e8893. | 2.5 | 27 |
| 78 | Primary Leptomeningeal ALK+ Lymphoma in a 13-year-old Child. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 963-967. | 0.6 | 25 |
| 79 | Epidermal Growth Factor Receptor/ β 2-Catenin/T-Cell Factor 4/Matrix Metalloproteinase 1: A New Pathway for Regulating Keratinocyte Invasiveness after UVA Irradiation. <i>Cancer Research</i> , 2009, 69, 3291-3299. | 0.9 | 25 |
| 80 | Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922. | 7.2 | 23 |
| 81 | Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Leukemia</i> , 2006, 20, 793-799. | 7.2 | 22 |
| 82 | Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. <i>American Journal of Hematology</i> , 2016, 91, 193-198. | 4.1 | 22 |
| 83 | Is Complicated Celiac Disease or Refractory Sprue an Intestinal Intra-Epithelial Cryptic T-Cell Lymphoma?. <i>Blood</i> , 1999, 93, 3154-3155. | 1.4 | 21 |
| 84 | Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1998, 23, 220-226. | 2.8 | 20 |
| 85 | AF4p12, a Human Homologue to the furry Gene of Drosophila, as a Novel MLL Fusion Partner. <i>Cancer Research</i> , 2005, 65, 6521-6525. | 0.9 | 20 |
| 86 | PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10357-10362. | 7.1 | 20 |
| 87 | CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 38061-38078. | 1.8 | 20 |
| 88 | Comparison of 60 or 90 mg/m ² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. <i>American Journal of Hematology</i> , 2015, 90, E29-30. | 4.1 | 19 |
| 89 | TAL1 expression does not occur in the majority of T-ALL blasts. <i>British Journal of Haematology</i> , 1998, 102, 449-457. | 2.5 | 18 |
| 90 | Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. <i>British Journal of Haematology</i> , 2012, 159, 599-613. | 2.5 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Association of a Duodenal Follicular Lymphoma and Hereditary Nonpolyposis Colorectal Cancer. <i>Modern Pathology</i> , 2000, 13, 586-590. | 5.5 | 17 |
| 92 | IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. <i>Leukemia</i> , 2005, 19, 2337-2338. | 7.2 | 14 |
| 93 | Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. <i>Cancer Medicine</i> , 2019, 8, 3846-3854. | 2.8 | 14 |
| 94 | Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. <i>Blood Advances</i> , 2020, 4, 3840-3849. | 5.2 | 13 |
| 95 | The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762. | 1.4 | 13 |
| 96 | Deregulated expression of the TAL1 gene by t(1;5)(p32;q31) in patient with T-cell acute lymphoblastic leukemia. , 1998, 23, 36-43. | | 12 |
| 97 | Sorafenib plus all-trans retinoic acid for <sc>AML</sc> patients with <i><sc>FLT</sc>3</i> and <i><sc>NPM</sc>1</i> mutations. <i>European Journal of Haematology</i> , 2014, 93, 533-536. | 2.2 | 12 |
| 98 | Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. <i>PLoS ONE</i> , 2020, 15, e0238795. | 2.5 | 12 |
| 99 | Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. <i>Leukemia Research</i> , 2019, 81, 82-87. | 0.8 | 11 |
| 100 | Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020, 12, 773. | 3.7 | 11 |
| 101 | Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. <i>Leukemia</i> , 2006, 20, 2178-2181. | 7.2 | 9 |
| 102 | A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 17-22. | 1.0 | 9 |
| 103 | A case of B-cell precursor acute lymphoblastic leukemia with <i>IL3-IGH</i> rearrangement revealed by thromboembolism and marked eosinophilia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2489-2492. | 1.3 | 9 |
| 104 | Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020, 12, 2044. | 3.7 | 8 |
| 105 | Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 174-175. | 1.0 | 7 |
| 106 | Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder. <i>Haematologica</i> , 2008, 93, 1081-1085. | 3.5 | 7 |
| 107 | CD34+CD38~CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. <i>Cancers</i> , 2020, 12, 1174. | 3.7 | 7 |
| 108 | Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... <i>Blood</i> , 2009, 114, 3080-3080. | 1.4 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Genomic landscape of hyperleukocytic acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 4. | 6.2 | 7 |
| 110 | Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.. <i>Blood</i> , 2004, 104, 2741-2741. | 1.4 | 6 |
| 111 | Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.. <i>Blood</i> , 2012, 120, 2879-2879. | 1.4 | 6 |
| 112 | Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, e88-e90. | 0.8 | 5 |
| 113 | A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study. <i>Clinical Biochemistry</i> , 2015, 48, 982-987. | 1.9 | 5 |
| 114 | Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300. | 7.2 | 5 |
| 115 | GATA2 deficiency phenotype associated with tandem duplication of <i>GATA2</i> and overexpression of <i>GATA2-AS1</i> . <i>Blood Advances</i> , 2021, 5, 5631-5635. | 5.2 | 5 |
| 116 | Acute monocytic leukemia with coexpression of minorBCR-ABL1 andPICALM-MLL10 fusion genes along with overexpression ofHOXA9. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 575-582. | 2.8 | 4 |
| 117 | PAX5A and PAX5B isoforms are both efficient to drive B cell differentiation. <i>Oncotarget</i> , 2018, 9, 32841-32854. | 1.8 | 4 |
| 118 | Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2066-2069. | 7.2 | 4 |
| 119 | The impact of chronic myeloid leukemia on employment: the French prospective study. <i>Annals of Hematology</i> , 2019, 98, 615-623. | 1.8 | 4 |
| 120 | Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. <i>European Journal of Haematology</i> , 2021, 107, 111-121. | 2.2 | 4 |
| 121 | International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. <i>Blood</i> , 2011, 118, 2535-2535. | 1.4 | 4 |
| 122 | Efficacy of Frontline 5-Azacytidine in Older AML Patient Unfit for Chemotherapy. <i>Blood</i> , 2011, 118, 2614-2614. | 1.4 | 4 |
| 123 | The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations. <i>Blood</i> , 2015, 126, 2542-2542. | 1.4 | 4 |
| 124 | A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. <i>Blood Cancer Journal</i> , 2022, 12, . | 6.2 | 4 |
| 125 | Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay. <i>Human Pathology</i> , 2007, 38, 1581-1582. | 2.0 | 3 |
| 126 | More than ten percent of relapses occur after five years in AML patients with NPM1 mutation. <i>Leukemia and Lymphoma</i> , 2020, 61, 1226-1229. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | The <i>CADM1</i> tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. <i>Blood Advances</i> , 2022, 6, 386-398. | 5.2 | 3 |
| 128 | Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1398-1406. | 1.3 | 3 |
| 129 | Outcome of relapsed/refractory AML patients with IDH1 ^{R132} mutations in real life before the era of IDH1 inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 473-476. | 1.3 | 2 |
| 130 | Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 2829-2829. | 1.4 | 2 |
| 131 | Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1651-1651. | 1.4 | 2 |
| 132 | Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice. <i>Blood</i> , 2016, 128, 1718-1718. | 1.4 | 2 |
| 133 | Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1636-1636. | 1.4 | 2 |
| 134 | Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 180. | 6.2 | 2 |
| 135 | The CALM- <i>AF10</i> fusion is a rare event in acute megakaryoblastic leukemia. <i>Leukemia</i> , 2007, 21, 2568-2569. | 7.2 | 1 |
| 136 | Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. <i>Leukemia Research</i> , 2018, 75, 7-10. | 0.8 | 1 |
| 137 | Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 2806-2806. | 1.4 | 1 |
| 138 | PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.. <i>Blood</i> , 2007, 110, 2806-2806. | 1.4 | 1 |
| 139 | Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. <i>Blood</i> , 2013, 122, 2681-2681. | 1.4 | 1 |
| 140 | Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2016, 128, 2892-2892. | 1.4 | 1 |
| 141 | Absence of SCL mutations in myeloid malignancies. <i>British Journal of Haematology</i> , 2003, 120, 482-483. | 2.5 | 0 |
| 142 | GATA2, a new oncogene of sporadic and familial acute myeloid leukemias. <i>Hematologie</i> , 2014, 20, 153-160. | 0.0 | 0 |
| 143 | Declined Presentation. <i>Experimental Hematology</i> , 2014, 42, S27. | 0.4 | 0 |
| 144 | Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.. <i>Blood</i> , 2007, 110, 978-978. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Abstract 3130: The short form of the receptor tyrosine kinase Ron is expressed in acute myeloid leukemia, regulated by methylation and sensitizes leukemic cells to c-Met inhibitors. , 2011, , . | | 0 |
| 146 | What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A. Blood, 2011, 118, 1351-1351. | 1.4 | 0 |
| 147 | Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. Blood, 2011, 118, 410-410. | 1.4 | 0 |
| 148 | T315I-Mutated BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc Finger (ZNF) Transcription Factors. Blood, 2013, 122, 4899-4899. | 1.4 | 0 |
| 149 | Abstract 2678: All-trans-retinoic acid as a new therapeutic approach to target isocitrate dehydrogenase mutations in acute myeloid leukemia. , 2014, , . | | 0 |
| 150 | Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML. Blood, 2015, 126, 90-90. | 1.4 | 0 |
| 151 | Abstract A27: Long noncoding RNA expression in cytogenetically normal acute myeloid leukemia identifies a distinct signature associated with NPM1 mutations. , 2016, , . | | 0 |
| 152 | Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. Blood, 2016, 128, 2861-2861. | 1.4 | 0 |
| 153 | Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine. Blood, 2018, 132, 1467-1467. | 1.4 | 0 |
| 154 | More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission. Blood, 2018, 132, 2802-2802. | 1.4 | 0 |
| 155 | TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine. Blood, 2018, 132, 2745-2745. | 1.4 | 0 |